Zacks Research Issues Positive Forecast for FMS Earnings

Fresenius Medical Care AG (NYSE:FMS) – Analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for shares of Fresenius Medical Care in a research note issued to investors on Tuesday, March 18th. Zacks Research analyst I. Bandyopadhyay now expects that the company will earn $0.44 per share for the quarter, up from their previous forecast of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q2 2025 earnings at $0.47 EPS, Q3 2025 earnings at $0.54 EPS, Q4 2025 earnings at $0.56 EPS, FY2025 earnings at $2.01 EPS, Q1 2026 earnings at $0.48 EPS, Q2 2026 earnings at $0.49 EPS, Q3 2026 earnings at $0.60 EPS, FY2026 earnings at $2.19 EPS and FY2027 earnings at $2.07 EPS.

Other analysts have also recently issued research reports about the stock. Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd. StockNews.com upgraded Fresenius Medical Care from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, Truist Financial raised their price target on Fresenius Medical Care from $23.00 to $25.00 and gave the company a “hold” rating in a report on Monday, January 6th.

Fresenius Medical Care Price Performance

Shares of NYSE:FMS opened at $24.63 on Thursday. The firm has a market cap of $14.45 billion, a price-to-earnings ratio of 20.35, a P/E/G ratio of 0.76 and a beta of 0.99. The firm has a fifty day moving average price of $23.82 and a 200 day moving average price of $22.31. Fresenius Medical Care has a fifty-two week low of $17.93 and a fifty-two week high of $25.25. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Hedge Funds Weigh In On Fresenius Medical Care

Institutional investors and hedge funds have recently made changes to their positions in the business. Millennium Management LLC lifted its holdings in shares of Fresenius Medical Care by 5,297.5% in the 4th quarter. Millennium Management LLC now owns 722,238 shares of the company’s stock valued at $16,351,000 after acquiring an additional 708,857 shares during the last quarter. Integral Health Asset Management LLC raised its position in Fresenius Medical Care by 33.3% during the fourth quarter. Integral Health Asset Management LLC now owns 600,000 shares of the company’s stock valued at $13,584,000 after purchasing an additional 150,000 shares during the period. Northern Trust Corp boosted its holdings in shares of Fresenius Medical Care by 45.9% in the 4th quarter. Northern Trust Corp now owns 362,190 shares of the company’s stock worth $8,200,000 after purchasing an additional 113,953 shares during the period. Moran Wealth Management LLC increased its position in shares of Fresenius Medical Care by 9.1% during the 4th quarter. Moran Wealth Management LLC now owns 254,710 shares of the company’s stock valued at $5,767,000 after purchasing an additional 21,334 shares during the last quarter. Finally, ABC Arbitrage SA purchased a new stake in Fresenius Medical Care during the 4th quarter valued at $4,215,000. 8.37% of the stock is owned by hedge funds and other institutional investors.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.